< Back to previous page
Project
Determination of the ideal concentration of BVL-GSK098 required to boost ETH activity
BioVersys’ Clinical Candidate BVL-GSK098 is a small molecule able to inhibit Mycobacterium tuberculosis transcription regulator, VirS. By doing so, BVL-GSK098 has been shown to boost bioactivation of ethionamide (ETH) and, consequently, to lower ETH MIC. In addition, since resistance to ETH is due to mutations in EthA, the enzyme responsible for ETH bioactivation, the presence of BVL-GSK098, which activates an EthA-independent - VirS-dependent bioactivation pathway of ETH, makes ETH-resistant Mtb again susceptible to low ETH concentrations.
ITM will provide to BioVersys as a service the determination of ETH MICs in the absence or in the presence of three concentrations of BVL-GSK098 against 100 Mtb clinical isolates of different lineages and/or representing at best Mtb geographical distribution. Scope of the service is the determination of the ideal concentration of BVL-GSK098 required to boost ETH activity in ≥90% of the clinical isolates.
ITM will provide to BioVersys as a service the determination of ETH MICs in the absence or in the presence of three concentrations of BVL-GSK098 against 100 Mtb clinical isolates of different lineages and/or representing at best Mtb geographical distribution. Scope of the service is the determination of the ideal concentration of BVL-GSK098 required to boost ETH activity in ≥90% of the clinical isolates.
Date:15 Aug 2020 → 31 Dec 2021
Project type:Service project